Literature DB >> 6185198

0-7-21 radiotherapy in nodular melanoma.

C R Johanson, A R Harwood, B J Cummings, I Quirt.   

Abstract

Fifty-four patients from August 1975 to March 1980 were treated with high dose per fraction (0-7-21) radiotherapy for malignant melanoma. The patients were subdivided into three clinical subtypes of disease: microscopic residual melanoma following surgery (22 patients), gross residual melanoma following surgery (nine patients), and recurrent melanoma (23 patients). Eighteen of 22 (82%) of patients treated for microscopic residual disease have been free of local recurrence to date. Ten of the 18 are alive and free of disease for up to 44 months following irradiation. Seven of nine (78%) patients treated for gross residual tumor have had no recurrence or progression of tumor in the irradiated volume, five of the nine achieved a complete remission and three are alive and free of disease at ten, 13, and 42 months, respectively. Twenty-three patients with recurrent melanoma were irradiated. Nine achieved a complete remission (39%) of tumor in the irradiated volume and three are alive and free of disease at up to 56 months following irradiation treatment. Three major complications of irradiation have been seen in the 54 patients treated. It is concluded that nodular melanoma is not a radioresistant tumor, large dose per fraction radiotherapy produces a high response rate of patients with measurable disease which is prolonged in some patients. The indications for radiotherapy in nodular melanoma are discussed and prospective studies of irradiation in melanoma are proposed.

Entities:  

Mesh:

Year:  1983        PMID: 6185198     DOI: 10.1002/1097-0142(19830115)51:2<226::aid-cncr2820510210>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Authors:  Hiroyuki Goto; Yoshio Kiyohara; Masahisa Shindo; Osamu Yamamoto
Journal:  Curr Treat Options Oncol       Date:  2019-03-27

2.  Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma.

Authors:  Carlos Conill; Izaskun Valduvieco; Josep Domingo-Domènech; Pedro Arguis; Sergi Vidal-Sicart; Antonio Vilalta
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

3.  Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control.

Authors:  E A Strom; M I Ross
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

4.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

5.  In Regard to Yerramilli et al's "Palliative Radiotherapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits".

Authors:  Ezra Hahn; Jonathan Livergant; Barbara-Ann Millar; Jolie Ringash; Rebecca Wong; Laura A Dawson; Padraig Warde; Bernard Cummings; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2020-05-11

6.  Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

Authors:  Francesco Cellini; Rossella Di Franco; Stefania Manfrida; Valentina Borzillo; Ernesto Maranzano; Stefano Pergolizzi; Alessio Giuseppe Morganti; Vincenzo Fusco; Francesco Deodato; Mario Santarelli; Fabio Arcidiacono; Romina Rossi; Sara Reina; Anna Merlotti; Barbara Alicja Jereczek-Fossa; Angelo Tozzi; Giambattista Siepe; Alberto Cacciola; Elvio Russi; Maria Antonietta Gambacorta; Marta Scorsetti; Umberto Ricardi; Renzo Corvò; Vittorio Donato; Paolo Muto; Vincenzo Valentini
Journal:  Radiol Med       Date:  2021-09-27       Impact factor: 3.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.